Heart Failure With Preserved Ejection Fraction (HFpEF) Clinical Trial
Official title:
Differences in Cardiopulmonary Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition in Patients With Suspected Heart Failure With Preserved Ejection Fraction
The correlation of coronary microvascular function and body composition with cardiopulmonary exercise capacity will be assessed in patients with heart failure with preserved ejection fraction.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility | Inclusion Criteria: - Age 20 to 80 - Typical/atypical chest pain or ischemic symptoms including dyspnea - No significant coronary artery stenosis (>50% stenosis) in coronary angiography or computed tomography - Left ventricular ejection fraction =50% Exclusion Criteria: - More than moderate valvular heart disease - Congenital heart disease - Chronic renal failure (estimated glomerular filtration rate <30 ml/min/1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis - Asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension - Receiving anticancer drugs - Vasculitis associated with autoimmune diseases - Patients with difficulty in performing exercise load evaluation (treadmill, bicycle ergometer) - Atrial fibrillation - Atrioventricular block with more than second degrees, symptomatic bradycardia, cryo-node failure syndrome, Wolff-Parkinson-White (WPW) patients |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Korea University Anam Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Korea University Anam Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Correlation of coronary blood flow with cardiopulmonary exercise capacity | Coronary blood flow is assessed by coronary flow reserve (CFR), which is defined as peak to baseline mean diastolic velocity of coronary flow.
In regard to cardiopulmonary exercise capacity, maximal oxygen consumption (VO2max) will be assessed. |
up to day 14 | |
Primary | Correlation of body composition with cardiopulmonary exercise capacity | In body composition analysis, skeletal muscle mass and body fat mass will be assessed.
In regard to cardiopulmonary exercise capacity, maximal oxygen consumption (VO2max) will be assessed. |
up to day 14 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
Recruiting |
NCT05441839 -
UK Heart Failure With Preserved Ejection Fraction
|
||
Completed |
NCT01989299 -
Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction
|
||
Terminated |
NCT03909295 -
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
|
Phase 3 | |
Completed |
NCT04327024 -
Study of Verinurad in Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
Active, not recruiting |
NCT05136820 -
Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study
|
N/A | |
Completed |
NCT03988634 -
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
|
Phase 3 | |
Recruiting |
NCT03876223 -
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
|
||
Completed |
NCT04232345 -
A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05792059 -
DevElopMent of Clinical PATHwaYs to the Diagnosis of Heart Failure With Preserved Ejection Fraction
|
||
Completed |
NCT03843060 -
A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01714752 -
Evaluation of Left Ventricular Filling Pressures During Exercise
|
N/A | |
Completed |
NCT06036186 -
Study for the Treatment of Heart Failure With Preserved Ejection Fraction Associated With High Blood Pressure Using Right Atrial Pacing Controlled by the PressurePaceTM System
|
N/A | |
Recruiting |
NCT05383287 -
Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)
|
||
Completed |
NCT03877224 -
DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
|
Phase 3 | |
Active, not recruiting |
NCT04847557 -
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
|
Phase 3 |